Mark Sullivan

2.5k citations

44 papers · 1.2k · h-index 12

Impact in

Hepatology top 1%
- Hepatitis C virus research
- Hepatitis Viruses Studies and Epidemiology
Epidemiology top 5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment

Papers in

Epidemiology 14
- Hepatitis B Virus Studies 8
Infectious Diseases 12
- HIV/AIDS drug development and treatment 8
- Parasitic Diseases Research and Treatment 3

Co-authors: Carol Brosgart (7 shared papers)K. Kleber (3 shared papers)Ramin Ebrahimi (3 shared papers)Peter Buggisch (2 shared papers)Marion G. Peters (2 shared papers)Paul Martin (3 shared papers)S. Xiong (2 shared papers)DF Gray (1 shared paper)
Journals: Journal of Hepatology (5 papers)Gastroenterology (4 papers)American Journal of Health-System Pharmacy (3 papers)PLoS neglected tropical diseases (3 papers)Drug Delivery and Translational Research (1 paper)
Partner nations: United States Australia United Kingdom

In The Last Decade

Mark Sullivan

40 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark Sullivan

Since Specialization

Citations

This map shows the geographic impact of Mark Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sullivan more than expected).

Fields of papers citing papers by Mark Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sullivan. The network helps show where Mark Sullivan may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Sullivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Sullivan Line = papers co-authored together Mark Sullivan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology ·Marion G. Peters, Hie‐Won Hann, Paul Martin, E. Jenny Heathcote, Peter Buggisch, R Rubin, Marc Bourlière, Kris V. Kowdley, Christian Trépo, DF Gray, Mark Sullivan, K. Kleber, Ramin Ebrahimi, S. Xiong, Carol Brosgart	2003	440
2	A framework for the development of effective anti-metastatic agents Nature Reviews Clinical Oncology ·Robin L. Anderson, Theo Balasas, Juliana Callaghan, R. Charles Coombes, JEFF EVANS, Jacqueline A. Hall, Sally Kinrade, David Jones, Paul S. Jones, Robert J. Jones, John F. Marshall, Maria Beatrice Panico, Jacqui Shaw, Patricia S. Steeg, Mark Sullivan, Warwick Tong, Andrew D. Westwell, James W.A. Ritchie	2018	245
3	Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study Gastroenterology ·Frederik Nevens, Janice Main, Pieter Honkoop, DL Tyrrell, Judy Barber, Mark Sullivan, Johan Fevery, RA De Man, H.C. Thomas	1997	239
4	Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours Journal of Immunological Methods ·Henrik N. Kløverpris, Anders Fomsgaard, Amanda Handley, Jim Ackland, Mark Sullivan, Philip Goulder	2010	38
5	Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques Vaccine ·Robert De Rose, Socheata Chea, C. Jane Dale, Jeanette C. Reece, Caroline S. Fernandez, Kim Wilson, Scott Thomson, Ian A. Ramshaw, Barbara E.H. Coupar, David B. Boyle, Mark Sullivan, Stephen J. Kent	2004	27
6	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever Drug Delivery and Translational Research ·Rosemary Wyber, Ben J. Boyd, Samantha Colquhoun, Bart J. Currie, Mark E. Engel, Joseph Kado, Ganesan Karthikeyan, Mark Sullivan, Anitá Saxena, Meru Sheel, Andrew C. Steer, Joseph Mucumbitsi, Liesl Zühlke, Jonathan R. Carapetis	2016	26
7	The Gravity Probe-B star-tracking telescope Advances in Space Research ·D.-H. Gwo, Sihong Wang, K. Bower, Donald E. Davidson, Paul Ehrensberger, Lynn W. Huff, (unknown), Mark Sullivan, K. Triebes, J. A. Lipa	2003	26
8	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet Gastroenterology ·Gregor J. Brown, A. James M. Daveson, Joanne Marjason, Rose A. Ffrench, Danielle Smith, Mark Sullivan, Jason A. Tye–Din, Robert P. Anderson	2011	25
9	Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis Journal of Hepatology ·Marion G. Peters, H.W. Hann, Paul Martin, E. Jenny Heathcote, Peter Buggisch, Alison Moorat, Mark Sullivan, K. Kleber, Ramin Ebrahimi, Shelly Xiong, Carol Brosgart	2002	21
10	Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years PLoS neglected tropical diseases ·Piero Olliaro, Annette C. Kuesel, Christine Halleux, Mark Sullivan, John C. Reeder	2018	17
11	Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV Journal of Hepatology ·Yves Benhamou, M. Bochet, Roland Tubiana, Vincent Thibault, L. Suflisseau, Mark Sullivan, Jim Rooney, Carol Brosgart, François Bricaire, Christine Katlama, Thierry Poynard	2002	16
12	Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials Human Vaccines ·Robert De Rose, Mark Sullivan, C. Jane Dale, Anthony D. Kelleher, Sean Emery, David A. Cooper, Ian A. Ramshaw, David B. Boyle, Stephen J. Kent	2006	11
13	Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients Journal of Hepatology ·Yves Benhamou, M. Bochet, Vincent Thibault, Vincent Cálvez, M.‐H. Fievet, Mark Sullivan, Carol Brosgart, Hamid Namini, Thierry Poynard, Christine Katlama	2002	11
14	Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐QT Study Clinical and Translational Science ·Sally Kinrade, Jay W. Mason, Carlos Sanabria, Craig R. Rayner, Julie Bullock, Stephanie H. Stanworth, Mark Sullivan	2018	11
15	LRO Diviner Lunar Radiometer Global Mapping Results and Gridded Data Product Lunar and Planetary Science Conference ·D. A. Paige, J. P. Williams, Mark Sullivan, B. T. Greenhagen	2011	9
16	Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection PLoS neglected tropical diseases ·Beesan Tan, Nicholas Opoku, Simon K. Attah, Kwablah Awadzi, Annette C. Kuesel, Janis K. Lazdins-Helds, Craig R. Rayner, Victoria Ryg-Cornejo, Mark Sullivan, Lawrence Fleckenstein	2022	8
17	Extravesical ureteral ectopia Urology ·Mark Sullivan, Luis Halpert, Clarence V. Hodges	1978	8
18	Moving candidate vaccines into development from research: lessons from HIV Immunology and Cell Biology ·Mark Sullivan	2009	6
19	Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy Journal of Hepatology ·C. Westland, H. Yang, William E. Delaney, Vincent Thibault, Y. Benhamou, Craig S. Gibbs, Michael D. Miller, Michael Wulfsohn, Mark Sullivan, John Fry, Carol Brosgart, S. Xiong	2003	6
20	Temperatures of the Lacus Mortis Region of the Moon Earth and Space Science ·J. P. Williams, B. T. Greenhagen, K. A. Bennett, D. A. Paige, Nandita Kumari, Caitlin Ahrens, Lior Rubanenko, Tyler Powell, Parvathy Prem, D. T. Blewett, Patrick Russell, P. O. Hayne, Mark Sullivan	2021	4

About Mark Sullivan

Mark Sullivan is a scholar working on Epidemiology, Infectious Diseases, Aerospace Engineering, Hepatology and Virology, having authored 44 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (8 papers), HIV/AIDS drug development and treatment (8 papers), Hepatitis C virus research (6 papers), HIV Research and Treatment (5 papers), Particle Accelerators and Free-Electron Lasers (3 papers), Immunotherapy and Immune Responses (3 papers), Parasitic Diseases Research and Treatment (3 papers) and Planetary Science and Exploration (3 papers). The work is most often cited by research in Hepatology (699 citations), Epidemiology (778 citations), Infectious Diseases (259 citations), Virology (52 citations) and Cancer Research (71 citations). Mark Sullivan has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Carol Brosgart, K. Kleber, Ramin Ebrahimi, Peter Buggisch, Marion G. Peters, Paul Martin, S. Xiong, DF Gray, E. Jenny Heathcote and R Rubin. Their work appears in journals such as Journal of Hepatology, Gastroenterology, American Journal of Health-System Pharmacy, PLoS neglected tropical diseases and Drug Delivery and Translational Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark Sullivan

Impact in

Papers in i

In The Last Decade

Mark Sullivan

Peers

Countries citing papers authored by Mark Sullivan

Fields of papers citing papers by Mark Sullivan

All Works

About Mark Sullivan

Explore authors with similar magnitude of impact

Papers in